Key facts
- This page summarizes Angelo Scopelianos's Form 4 filing for Axogen, Inc. (AXGN).
- 9 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 25 Mar 2024, 21:37.
Angelo Scopelianos - 16 Mar 2024 Form 4 Insider Report for Axogen, Inc. (AXGN)
- Reporting relationship
- Chief R&D Officer
- Issuer ticker
- AXGN
- Reported as of
- 16 Mar 2024
- Net transaction value
- -$52,846
- SEC form
- 4
- Accepted by SEC
- 25 Mar 2024, 21:37:10 UTC
- Prior SEC filing
- 13 Oct 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Angelo Scopelianos
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Angelo Scopelianos filed Form 4 for Axogen, Inc. (AXGN) on 25 Mar 2024.
Change
- Previous filing in this sequence was filed on 13 Oct 2023.
- Current net transaction value: -$52,846.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
AXGN
transaction
Common Stock
Options Exercise
- Transaction value
- $0
- Shares
- +21,281
- Change %
- +58%
- Price
- $0.000000
- Shares after
- 58,250
- Date
- 16 Mar 2024
- Ownership
- Direct
- Footnotes
- F1
AXGN
transaction
Common Stock
Sale
- Transaction value
- $40,328
- Shares
- -5,251
- Change %
- -9%
- Price
- $7.68
- Shares after
- 52,999
- Date
- 21 Mar 2024
- Ownership
- Direct
- Footnotes
- F2
AXGN
transaction
Common Stock
Options Exercise
- Transaction value
- $0
- Shares
- +4,125
- Change %
- +7.8%
- Price
- $0.000000
- Shares after
- 57,124
- Date
- 16 Mar 2024
- Ownership
- Direct
- Footnotes
- F1
AXGN
transaction
Common Stock
Sale
- Transaction value
- $7,834
- Shares
- -1,020
- Change %
- -1.8%
- Price
- $7.68
- Shares after
- 56,104
- Date
- 21 Mar 2024
- Ownership
- Direct
- Footnotes
- F2
AXGN
transaction
Common Stock
Options Exercise
- Transaction value
- $0
- Shares
- +2,500
- Change %
- +4.5%
- Price
- $0.000000
- Shares after
- 58,604
- Date
- 21 Mar 2024
- Ownership
- Direct
- Footnotes
- F1
AXGN
transaction
Common Stock
Sale
- Transaction value
- $4,685
- Shares
- -610
- Change %
- -1%
- Price
- $7.68
- Shares after
- 57,994
- Date
- 21 Mar 2024
- Ownership
- Direct
- Footnotes
- F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
AXGN
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -21,281
- Change %
- -50%
- Price
- $0.000000
- Shares after
- 21,282
- Date
- 16 Mar 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 21,281
- Exercise price
- Footnotes
- F3, F4
AXGN
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -4,125
- Change %
- -50%
- Price
- $0.000000
- Shares after
- 4,125
- Date
- 16 Mar 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 4,125
- Exercise price
- Footnotes
- F3, F5
AXGN
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -2,500
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 16 Mar 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 2,500
- Exercise price
- Footnotes
- F3, F6
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 6 footnotes
Footnote F1
This reflects the number of restricted stock units that became vested as of March 16, 2024.
Footnote F2
Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
Footnote F3
Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.
Footnote F4
All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2026 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregateshares vest on March 16, 2024 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.
Footnote F5
All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2025 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2023, 25% of the aggregate shares vest on March 16, 2024, and 25% of the aggregate shares vest on March 16, 2025. Vested shares will be delivered to the reporting person upon the vesting date.
Footnote F6
All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2024 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2022 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.